Decoy Therapeutics Inc. · NASDAQ:DCOY
Decoy Therapeutics — Investor Presentation (June 2026)
18 slides from Decoy Therapeutics's investor presentation, June 2026
Slide 1: Corporate Presentation
NASDAQ: DCOY decoytx.com One drug. Many viruses. Many people June 2026 Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy Therapeutics Inc. ("Decoy" or the "Company"), including statements regarding the expected achievement of milestones for its le
Slide 3: One drug. Many viruses. Many people.
INVESTMENT HIGHLIGHTS 250+ $6.5M Human-infecting viruses Non-dilutive funding1 One drug. One conserved target; current programs Funding from leading global health, designed to address up to 70%+ of annual technology and government organizations. Many viruses. virus positive respiratory viral infecti
Slide 4: A single conserved target transforms antiviral discovery, development & use
T H E D - M AV P L AT F O R M · V I R AL F U S I O N I N H I B I T I O N A single conserved target transforms antiviral discovery, development & use Viral Fusion Inhibition One Drug – Multi Virus T H E T AR G E T · H O W I T W O R K S Viral membrane → ··· ONE DRUG MULTIPLE VIRUSES ENABLES → WHAT IT
Slide 5: Multi-antiviral business model: multiple products from one API
M U L TI - AN T I V I R AL B U S I N E S S M O D E L Formulation as pipeline: Multiple products from one multi-viral API1 Leverage shared supply chain and safety record with multiple formulations designed to the medical need Upper Respiratory 1 1Active Pharmaceutical Ingredient Tract Effective again
Slide 6: D-MAVs are designed at unprecedented speed
T H E I M P ³ AC T T M E N G I N E D-MAVs are designed at unprecedented speed Our AI/ML design-build-test-learn loop generates lead candidates in weeks to months — implemented on Google Cloud. GENERATION 0 GENERATION 5 L L Dimeric ‘wild-type’ L Monomeric optimized E fusion inhibitor fusion inhibitor
Slide 7: Targeting up to 70% of serious respiratory viral infections
D-MAV PIPELINE Targeting up to 70% of serious respiratory viral infections Program Indication Discovery Preclinical Phase 1 Phase 2 Key Highlights DCOY-CoV Pan-coronavirus - Gates Foundation funding Broad-Acting Fusion protection for high-risk & development to IND Inhibitor immunocompromised - Phase
Slide 8: Lead program DCOY-CoV: pan-coronavirus D-MAV for high-risk patients
LEAD PROGRAM L E AD P R O G R AM · D C O Y - C o V Pan-coronavirus D-MAV Lead targeting high-risk patients Advancing toward a Phase 1 study expected to commence 2027 U.S. ANNUAL BURDEN MARKET VALIDATION CORE MARKET ~290K-450K ~34K-53K $5.7B 20M Paxlovid sales 2024 Immune compromised US + EU Hospital
Slide 9: Pan-coronavirus activity from a single D-MAV
L E AD P R O G R AM · D C O Y - C o V Pan-coronavirus activity Very Robust Results from a single D-MAV DCOY-CoV Pan-Coronavirus Activity Heat Map - Nanomolar activity IC50 in antiviral assays — 1st generation vs. optimized Lead Candidates - All known human More 1st Lead Candidates coronaviruses test
Slide 10: Highly effective in vivo, pre- and post-viral exposure
L E AD P R O G R AM · D C O Y - C O V Highly effective in vivo, pre- and post-viral exposure Once daily intra-nasal (IN) dosing prevents and treats SARS-CoV-2 infections in nose & lungs for up to 36 hours post exposure PRE-EXPOSURE PROPHYLAXIS (PREP) POST-EXPOSURE PROPHYLAXIS (PEP) MOUSE PK Body wei
Slide 11: An evolving COVID market
L E AD P R O G R AM · D C O Y - C o V An evolving COVID market EM ERGING M ARKET STRUCTURE MPro inhibitors (Paxlovid) $5.7B1 Prophylactic mAb $1.5B2 Established, effective standard of care (SOC) for non-drug/drug Vaccine-comparable 3–6 months Pre-Exposure Prophylaxis interaction (DDI) patients; next
Slide 12: DCOY-CoV's profile is highly differentiated, including pan-coronavirus activity
L E AD P R O G R AM · D C O Y - C o V DCOY-CoV’s profile is highly differentiated, including pan-coronavirus activity In vitro activity against multiple viral families COM PETITIVE DIFFERENTI ATION Prophylactic Treatment mAb MPro DCOY-CoV Target point of infection ✕ ✕ ✓ First step of infection ✓ ✕ ✓
Slide 13: A single D-MAV targeting multiple respiratory viral families
S E C O N D P R O G R AM · D C O Y - T R I A single D-MAV targeting multiple respiratory viral families Pan-Flu + Pan-Coronavirus + Pan-Paramyxovirus: majority of severe virally-driven lower respiratory tract infections U.S. ANNUAL BURDEN SCOPE OF DISEASE ~1.59M ~138.5K 55-70% Combined Annual Hospit
Slide 14: In vitro results show broad activity across respiratory virus families
S E C O N D P R O G R AM · D C O Y - T R I In vitro results show broad activity across respiratory virus families Targeting conserved viral fusion is highly effective across Class I fusion respiratory viruses. Breadth conserved across multiple D-MAVs. PROOF OF CONCEPT CORONAVIRUS PARAMYXOVIRUS INFLU
Slide 15: 2 Programs in the clinic in 24 months — human POC via Challenge Model
D E V E L O P M E N T P AT H 2 Programs in the clinic in 24 months — human POC via Challenge Model Human challenge studies significantly de-risk the path market approval Traditional path 3–5 yrs to POC Speed to data Lower capital High success rates Human POC at ~ Fast, localized ID > other TAs, Deco
Slide 16: Proven Development Expertise with Multiple Drugs Approved Across Therapeutic Areas
Proven Development Expertise with Multiple Drugs Approved Across Therapeutic Areas Rick Pierce, CEO Mark Rosenblum CFO Barb Hibner, PhD CSO Investment Banking, ActiveCare, Advaxis, Bayer, Chiron, Serial Biotech Entrepreneur Haskin & Sells (Deloitte) Takeda Michael Lipp, PhD CTO Peter Marschel, MS MB
Slide 17: Why Now?
Why Now? 2 in 2 THE DECOY DIFFERENCE A designed multi-antiviral platform with two programs running in parallel to human proof of concept. Speed Two clinical programs in 2 years. without shortcuts. Capital allocated to the molecules most Human POC in 24 months from FIH. likely to work. $9.2B $5.7B $6
Slide 18: Thank You!
NASDAQ: DCOY decoytx.com One drug. Many viruses. Many people Thank You!
Decoy Therapeutics — Investor Presentation (June 2026) on 6ix